Hyderabad, Sept 3 (UNI) Dr Reddy’s Laboratories, on Thursday announced the launch of Methylphenidate Hydrochloride Extended-Release Tablets USP, in the US market.
The tablets which are available in the strength of 18 mg, 27 mg, 36 mg and 54 mg in bottle count sizes of 100, a therapeutic equivalent generic version of Concerta, was approved by the US Food and Drug Administration (USFDA), Hyderabad-based pharmaceutical company said in a statement here.
The Concerta brand and generic market had US sales of approximately $1.159 billion MAT for the most recent twelve months ending in June 2020 according to IQVIA Health.
Methylphenidate hydrochloride extended-release tablets should be given cautiously to patients with a history of drug dependence or alcoholism.
